Michael Halassa, a prominent neuroscientist at Tufts University School of Medicine, sheds light on this complexity. He describes the brain’s inherent uncertainty, likening its neural networks to groups of neurons casting votes—some optimistic and others pessimistic. This interplay of signals forms the basis for our decision-making processes. When this balance tips, the brain can misinterpret reality. For instance, individuals with schizophrenia may assign excessive significance to random events, while those with obsessive-compulsive disorder may become trapped in rigid thought patterns.

Studying these neural misfires has been a daunting challenge for scientists. Halassa emphasizes that the brain communicates through single neurons; however, the primary tool used to study brain activity in humans—functional magnetic resonance imaging (fMRI)—tracks blood flow rather than the electrical signals emitted by individual brain cells. This inherent limitation complicates our understanding of how various circuits influence thought and behavior.

To bridge this gap and develop a more nuanced understanding of brain function, researchers have combined insights from single-cell studies conducted on animals with human imaging data and behavioral analyses. A breakthrough in this research trajectory is a new computational model known as CogLinks. This innovative model is grounded in biological realism and provides an unprecedented look into how brain circuits formulate decisions and adapt when faced with changing rules in their environment.

CogLinks sets itself apart by integrating biological plausibility in its architecture, mirroring the connectivity of biological neurons. Moreover, it encodes how these neurons assess value amid often vague and incomplete external stimuli. Unlike many traditional AI systems, which often operate as “black boxes” obscuring their inner workings, CogLinks offers transparency. Researchers can discern how the digital neurons within the model create a relationship between structural properties and functional outcomes. This visibility allows them to trace how this virtual brain acquires knowledge through experiences and adjusts its responses based on new data.

In a recent study published in the esteemed journal Nature Communications, Halassa and his collaborative team from the Massachusetts Institute of Technology (MIT) harnessed the power of CogLinks to investigate how distinct brain circuits contribute to flexible thinking. The model rouses comparisons to a flight simulator tailored for cognitive processes, allowing researchers to experiment with how critical brain pathways go awry under different scenarios. By deliberately weakening the connection between two simulated brain regions—the prefrontal cortex and the mediodorsal thalamus—the team observed a detrimental shift towards slower and more habitual learning. This result underscores the importance of this neural pathway in facilitating adaptability in thought and behavior.

To validate the predictions established by the CogLinks model in human subjects, the research team conducted a complementary fMRI study, jointly overseen by Burkhard Pleger from Ruhr-University Bochum and Halassa himself. During this experimental phase, participants engaged in a game where the rules occasionally changed without warning. The results aligned perfectly with the model’s projections: the prefrontal cortex was responsible for planning and executing decisions based on established rules, while the striatum, a deep-seated region of the brain, governed habitual responses. Notably, the mediodorsal thalamus became particularly active when players recognized the alteration in rules and adjusted their strategies accordingly.

These imaging results confirmed the role of the mediodorsal thalamus as a pivotal switchboard linking two primary learning systems in the brain—flexible and habitual. This neural coordination is crucial for enabling the brain to recognize when contextual information shifts and to switch strategies to accommodate new circumstances. The implications of this research are far-reaching, providing insight into the fundamental mechanisms underlying decision-making and behavioral adaptation.

Halassa envisions that this groundbreaking research lays the foundation for a next-generation approach to psychiatric treatment, which he conceptualizes as “algorithmic psychiatry.” This framework would utilize advanced computer models to unravel how changes in brain circuits contribute to mental illness, paving the way for the identification of biological markers that can be targeted for more precise treatments.

Mien Brabeeba Wang, the lead author of the CogLinks study and a doctoral student at MIT in Halassa’s lab, underscores the relevance of this research in connecting genetic knowledge to cognitive symptoms associated with psychiatric conditions. Wang elaborates on the significance of this study’s findings, noting that many genetic mutations linked to schizophrenia influence chemical receptors distributed throughout the brain. Future implementations of CogLinks could illuminate how such widespread molecular alterations hinder the brain’s capacity to organize information, ultimately affecting its proficiency in flexible thinking.

The research findings detailed in the CogLinks study received support from several significant grants awarded by the National Institutes of Health’s National Institute of Mental Health, highlighting the collaborative effort invested into elucidating these complex cognitive processes. Additional funding came from the National Science Foundation, enabling the researchers to explore this critical intersection of neuroscience and artificial intelligence.

With groundbreaking advancements in comprehension of brain function being a continual pursuit, emerging technologies like CogLinks stand at the forefront of neuroscience. As researchers strive to uncover the unseen patterns that guide decision-making and behavior, the potential applications of this knowledge will undoubtedly expand, impacting our understanding of mental health and the treatment of psychiatric disorders in meaningful ways.

As research in this field progresses, questions remain about how we can harness the insights derived from advanced computational models to propel innovations in psychiatric treatments and interventions. As the intersection of neuroscience and artificial intelligence continues to evolve, patient outcomes could significantly improve, shifting the paradigm of how mental health challenges are approached and treated.

The CogLinks model represents a remarkable convergence of biological realism and computational prowess, opening new avenues for exploration in understanding both the mechanics of the brain and the complexities of human behavior. As this technology advances, it promises to uncover the intricate details that underpin our thoughts, decisions, and ultimately our mental health.

Subject of Research: Neural basis of uncertainty processing in decision making.
Article Title: The neural basis for uncertainty processing in hierarchical decision making.
News Publication Date: 16-Oct-2025.
Web References: http://dx.doi.org/10.1038/s41467-025-63994-y
References: Nature Communications.
Image Credits: N/A.

Keywords

Neuroscience, Psychiatric disorders, Mental health, Psychiatry, Artificial intelligence.

Cognitive dysfunction in schizophrenia extends beyond the well-recognized positive and negative symptoms, infiltrating domains vital for everyday functioning such as memory, attention, executive functioning, and social cognition. These deficits pose significant barriers to patients’ social reintegration and quality of life, compounding the burdens shouldered by families and healthcare systems. Recognizing this, the study adopted a multistage stratified sampling method to enroll a large cohort of 1,274 patients, ensuring a rigorous and representative sample capable of yielding generalizable insights into this pressing issue.

One of the most striking findings of the study is the alarmingly high prevalence of cognitive impairment in this patient population, with approximately two-thirds (66.2%) exhibiting substantial dysfunction despite stable disease status and ongoing treatment. This challenges prior assumptions that effective symptom control via medication necessarily translates to cognitive preservation and underscores the urgent need for dedicated cognitive assessment and targeted interventions within routine psychiatric care.

The investigation delved deeply into various predictors of cognitive performance using binary logistic regression analysis, revealing a complex interplay of pharmacological, clinical, and demographic factors. Foremost among these was the use of first-generation antipsychotics (FGAs), which emerged as the most significant risk factor. The odds ratio for FGAs implicated in cognitive decline was an extraordinary 9.246, indicating a profound association between these older agents and worsened cognitive outcomes. This highlights growing concerns about the neurocognitive side effects of FGAs compared to their second-generation counterparts.

Beyond pharmacotherapy, the study illuminated other critical contributors to cognitive impairment. A positive family history of psychiatric conditions doubled the odds of cognitive dysfunction, suggesting genetic or environmental vulnerabilities that predispose patients to poorer cognitive trajectories. Negative symptoms — characterized by social withdrawal, apathy, and diminished emotional expression — were similarly linked to cognitive challenges, aligning with existing literature that underscores their detrimental impact on brain function and rehabilitation potential.

The analysis further identified the influence of adjunct medications such as mood stabilizers and anticholinergic drugs, both associated with increased risk of cognitive deficits. These findings hint at the nuanced effects of polypharmacy, where therapeutic regimens intended to stabilize mood or mitigate side effects may inadvertently exacerbate cognitive decline. Combined medication use also posed heightened risk, suggesting the necessity of cautious prescribing practices and vigilant monitoring.

Physical health parameters were not overlooked. Elevated body mass index (BMI) emerged as a subtle yet significant factor contributing to cognitive impairment. This reinforces the burgeoning evidence linking metabolic disturbances to neurocognitive dysfunction and raises important considerations for holistic patient management, encompassing physical and mental health domains.

Interestingly, longer duration of formal education was associated with a slight increase in risk, a counterintuitive finding that may reflect complex socio-educational dynamics or illness-related factors. Similarly, prolonged illness duration correlated with cognitive deficits, reinforcing the cumulative burden of schizophrenia over time on cerebral integrity.

Contrasting these risk factors, the study identified two protective factors with notable potential for clinical leverage. First, patients prescribed 5-HT1A receptor partial agonists exhibited significantly lower odds of cognitive impairment, underscoring the neuroprotective promise of targeting serotonergic pathways. This aligns with emerging pharmacological paradigms that prioritize cognitive preservation alongside symptom control. Secondly, having more children correlated with improved cognitive function, a finding that invites further exploration into psychosocial and motivational variables that may buffer cognitive decline.

The logistic regression model designed to predict cognitive impairment demonstrated respectable accuracy, with a sensitivity of 66.5% and specificity of 88.0%. This predictive capability offers a valuable tool for clinicians aiming to stratify patients by cognitive risk and tailor interventions accordingly.

The implications of these findings are both wide-ranging and urgent. The pronounced cognitive burden among stably medicated patients underscores the limitations of current antipsychotic therapies and the necessity for integrated treatment models that address cognitive health proactively. The outsized negative impact of FGAs calls for re-evaluation of their role in contemporary psychiatric practice, especially given the availability of newer agents with more favorable cognitive profiles.

Moreover, the highlighting of polypharmacy and adjunctive medications as risk factors directs attention to the intricate balancing act required in managing complex symptom constellations without compromising cognition. The associations with BMI and psychosocial variables reinforce the importance of comprehensive care approaches that extend beyond pharmacology to encompass lifestyle, physical health, and social support.

This study’s real-world clinical design bolsters its relevance, as it captures patient experiences within standard care settings rather than controlled trials, thereby enhancing the translational value of its conclusions. The findings prompt psychiatrists and mental health professionals to intensify their focus on cognitive assessments, employ evidence-based strategies to minimize cognitive decline, and explore novel therapeutic avenues including serotonin receptor modulation.

As schizophrenia continues to pose formidable challenges across clinical and societal domains, elucidating the factors that shape cognitive outcomes represents a critical frontier. This research marks a significant advance, offering a detailed map of risk and protective elements that can inform personalized medicine approaches and potentially alleviate the enduring cognitive burden that diminishes patients’ quality of life worldwide.

In summary, cognitive impairment in stable schizophrenia is alarmingly prevalent and influenced by a constellation of modifiable and non-modifiable factors. The detrimental role of first-generation antipsychotics and polypharmacy emerges vividly, alongside physiological and psychosocial determinants. Protective associations with serotonin receptor partial agonists and family dynamics highlight promising pathways for intervention. These insights compel a paradigm shift toward comprehensive, cognition-focused management strategies to improve long-term outcomes for individuals living with schizophrenia.

Subject of Research: Cognitive impairment and influencing factors in patients with stable schizophrenia on regular medication.

Article Title: Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study.

Article References:
Ji, Z., Yao, F., Liu, H. et al. Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study. BMC Psychiatry 25, 819 (2025). https://doi.org/10.1186/s12888-025-07297-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07297-y